Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

HIV Serodisclosure and Sexual Behavior During International Travel.

Truong HM, Chen YH, Grasso M, Robertson T, Tao L, Fatch R, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT.

Sex Transm Dis. 2016 Jul;43(7):459-64. doi: 10.1097/OLQ.0000000000000464.

2.

Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer.

Puntoni M, Petrera M, Campora S, Garrone E, Defferrari C, Torrisi R, Johansson H, Bruno S, Curotto A, DeCensi A.

Cancer Prev Res (Phila). 2016 Jun;9(6):437-44. doi: 10.1158/1940-6207.CAPR-15-0345. Epub 2016 Apr 4.

3.

Navigating Barriers to Vocational Rehabilitation for HIV-Positive Persons.

Gómez W, Flentje A, Schustack A, Ramirez-Forcier J, Andrews B, Dilworth SE, Riley ED, Curotto A, Carrico AW.

AIDS Behav. 2016 May;20(5):1132-42. doi: 10.1007/s10461-015-1261-1.

4.

Gay and bisexual men engage in fewer risky sexual behaviors while traveling internationally: a cross-sectional study in San Francisco.

Truong HM, Fatch R, Grasso M, Robertson T, Tao L, Chen YH, Curotto A, McFarland W, Grant RM, Reznick O, Raymond HF, Steward WT.

Sex Transm Infect. 2015 May;91(3):220-5. doi: 10.1136/sextrans-2014-051660. Epub 2014 Oct 29.

5.

Balancing theory and practice in respondent-driven sampling: a case study of innovations developed to overcome recruitment challenges.

Truong HM, Grasso M, Chen YH, Kellogg TA, Robertson T, Curotto A, Steward WT, McFarland W.

PLoS One. 2013 Aug 21;8(8):e70344. doi: 10.1371/journal.pone.0070344. eCollection 2013.

6.

[Intravesical chemotherapy].

Curotto AG.

Urologia. 2013;80 Suppl 21:20-3. doi: 10.5301/RU.2013.10857. Epub 2013 Mar 22. Italian.

PMID:
23559134
7.

Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study.

Gontero P, Oderda M, Altieri V, Bartoletti R, Cai T, Colombo R, Curotto A, Di Stasi S, Maffezzini M, Tamagno S, Serretta V, Sogni F, Terrone C, Tizzani A, Morgia G, Mirone V, Carmignani G.

Urol Int. 2011;86(1):19-24. doi: 10.1159/000321926. Epub 2010 Dec 30.

PMID:
21196690
8.

[Early vs delayed radical cystectomy compared in highgrade superficial bladder tumors].

Varca V, Simonato A, Esposito M, Curotto A, Orlandini M, Rikani E.

Urologia. 2009 Apr-Jun;76(2):83-6. Italian.

PMID:
21086302
9.

Comparing internet-based and venue-based methods to sample MSM in the San Francisco Bay Area.

Raymond HF, Rebchook G, Curotto A, Vaudrey J, Amsden M, Levine D, McFarland W.

AIDS Behav. 2010 Feb;14(1):218-24. doi: 10.1007/s10461-009-9521-6. Epub 2009 Jan 22.

PMID:
19160034
10.

Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer.

Puntoni M, Zanardi S, Branchi D, Bruno S, Curotto A, Varaldo M, Bruzzi P, Decensi A.

Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):979-83.

11.

Pre and postoperative quantitative detection of fragments of cytokeratins 8 and 18 (UBC IRMA) as markers of early recurrence of superficial bladder tumor.

Gacci M, Serni S, Lapini A, Giubilei G, Dal Canto M, Paladini S, Curotto A, Gallo F, Carmignani G, Carini M.

Arch Ital Urol Androl. 2006 Mar;78(1):5-10.

PMID:
16752880
12.

Intravesical gemcitabine in superficial bladder cancer: a phase II safety, efficacy and pharmacokinetic study.

Mattioli F, Curotto A, Manfredi V, Gosmar M, Garbero C, Ambruosi C, Carmignani G, Martelli A.

Anticancer Res. 2005 May-Jun;25(3c):2493-6.

13.

Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point.

Decensi A, Torrisi R, Bruno S, Costantini M, Curotto A, Nicolò G, Malcangi B, Baglietto L, Bruttini GP, Gatteschi B, Rondanina G, Varaldo M, Perloff M, Malone WF, Bruzzi P.

Cancer Epidemiol Biomarkers Prev. 2000 Oct;9(10):1071-8.

14.

Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial.

Bruno S, Torrisi R, Costantini M, Baglietto L, Fontana V, Gatteschi B, Melioli G, Nicolo G, Curotto A, Malcangi B, Bruttini GP, Varaldo M, Bruzzi P, Decensi A.

J Cell Biochem. 1999 Dec;76(2):311-21.

PMID:
10618647
15.

Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy.

Sanguineti G, Orsatti M, Sormani MP, Canobbio L, Curotto A, Tognoni P, Giudici S, Franzone P, Boccardo F, Vitale V.

Cancer J Sci Am. 1997 Jul-Aug;3(4):213-23.

PMID:
9263627
16.

Phenotypic, functional and molecular analysis of lymphocytes associated with bladder cancer.

Bruno S, Machí AM, Semino C, Meta M, Ponte M, Varaldo M, Curotto A, Ferlazzo G, Decensi A, Melioli G.

Cancer Immunol Immunother. 1996 Jan;42(1):47-54.

PMID:
8625366
17.

Combination therapy with subcutaneous interleukin-2 and interferon-alpha in advanced renal cancer patients with poor prognostic factors.

Canobbio L, Curotto A, Cannata D, Miglietta L, Lavarello A, Giglio C, Franchini R, Cussotto M, Boccardo F.

Anticancer Res. 1996 Jan-Feb;16(1):541-4.

PMID:
8615668
18.

Intravesical idarubicin: a dose-finding study.

Boccardo F, Cannata D, Cussotto M, Schenone M, Curotto A.

Cancer Chemother Pharmacol. 1996;38(1):102-5.

PMID:
8603442
19.

Alternating chemo-radiotherapy in bladder cancer: a conservative approach.

Orsatti M, Curotto A, Canobbio L, Guarneri D, Scarpati D, Venturini M, Franzone P, Giudici S, Martorana G, Boccardo F, et al.

Int J Radiat Oncol Biol Phys. 1995 Aug 30;33(1):173-8.

PMID:
7642415
20.

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with interleukin-2 and interferon-alpha.

Canobbio L, Rubagotti A, Miglietta L, Cannata D, Curotto A, Amoroso D, Boccardo F.

J Cancer Res Clin Oncol. 1995;121(12):753-6.

PMID:
7499447
21.

DNA flow cytometry as a surrogate end-point in patients with superficial bladder cancer treated with 4-HPR.

Decensi A, Curotto A, Bruno S, Costantini M, Torrisi R, Gatteschi B, Cussotto M, Pizzorno R, Quattrini S, Repetto U, et al.

Eur J Cancer Prev. 1994 Jul;3(4):377-9. No abstract available.

PMID:
7950899
22.

Carboplatin, methotrexate, and vinblastine in the treatment of patients with advanced urothelial cancer. A phase II trial.

Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A, Martorana G.

Cancer. 1994 Apr 1;73(7):1932-6.

PMID:
8137220
23.

Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point.

Decensi A, Bruno S, Costantini M, Torrisi R, Curotto A, Gatteschi B, Nicolò G, Polizzi A, Perloff M, Malone WF, et al.

J Natl Cancer Inst. 1994 Jan 19;86(2):138-40. No abstract available.

PMID:
8271297
24.

Low activity of circadian continuous fluorodeoxyuridine (fudr) chemotherapy in poor-prognosis metastatic renal-cancer.

Miglietta L, Canobbio L, Cannata D, Curotto A, Bertiriboli F, Giuliani L, Boccardo F.

Oncol Rep. 1994 Jan;1(1):121-3.

PMID:
21607319
25.

Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study.

Boccardo F, Cannata D, Rubagotti A, Guarneri D, Decensi A, Canobbio L, Curotto A, Martorana G, Pegoraro C, Selvaggi F, et al.

J Clin Oncol. 1994 Jan;12(1):7-13.

PMID:
8270987
26.

Activity of 4-HPR in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint.

Decensi A, Bruno S, Giaretti W, Torrisi R, Curotto A, Gatteschi B, Geido E, Polizzi A, Costantini M, Bruzzi P, et al.

J Cell Biochem Suppl. 1992;16I:139-47.

PMID:
1305678
27.

Phase II study of navelbine in advanced renal cell carcinoma.

Canobbio L, Boccardo F, Guarneri D, Calabria C, Decensi A, Curotto A, Martorana G, Giuliani L.

Eur J Cancer. 1991;27(6):804-5. No abstract available.

PMID:
1829928
28.

Neoadjuvant or definitive alternating chemotherapy and radiotherapy for infiltrating bladder cancer.

Venturini M, Merlano M, Michelotti A, Martorana G, Curotto A, Scarpati D, Orsatti M, Giuliani L, Rosso R.

Am J Clin Oncol. 1989 Feb;12(1):63-7.

PMID:
2912021
29.

Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma.

Sertoli MR, Brunetti I, Ardizzoni A, Falcone A, Guarneri D, Boccardo F, Martorana G, Curotto A, Sicignano A, Rosso R, et al.

Am J Clin Oncol. 1989 Feb;12(1):43-5.

PMID:
2492141
30.

Alternated pre-cystectomy chemo-radiotherapeutic treatment in patients with locally advanced bladder cancer: a preliminary report.

Martorana G, Giberti C, Curotto A, Bonamini A, Pizzorno R, Oneto F, Michelotti A, Venturini M, Merlano M, Scarpati D, et al.

Prog Clin Biol Res. 1988;260:591-8. No abstract available.

PMID:
3129739
31.

Treatment of urinary tract infections with ciprofloxacin.

Martorana G, Giberti C, Pizzorno R, Bonamini A, Oneto F, Curotto A, Soro O.

Clin Ther. 1988;10(5):516-20.

PMID:
2856593
32.

Supplemental Content

Loading ...
Support Center